Multiple myeloma is not an autoimmune disease. It is a blood cancer, specifically a malignancy of plasma cells in the bone marrow. The confusion is understandable because both conditions involve the immune system, and there are real overlaps between the two. But the underlying problem in multiple myeloma is uncontrolled cell growth, not the immune system attacking healthy tissue.
What Multiple Myeloma Actually Is
Plasma cells are white blood cells that normally produce antibodies to fight infections. In multiple myeloma, a single plasma cell becomes malignant and begins copying itself uncontrollably. These cloned cells accumulate in the bone marrow and churn out massive quantities of a single, nonfunctional protein called a monoclonal paraprotein. Unlike the diverse antibodies your body normally makes to fight different threats, this paraprotein does nothing useful. It just builds up.
That buildup, combined with the crowding of normal bone marrow, causes the hallmark problems of the disease. Doctors look for a pattern sometimes called CRAB: high calcium levels from bone breakdown, kidney damage from the excess protein, anemia from disrupted blood cell production, and bone lesions where the cancer has eaten away at the skeleton. About 96% of cases are already widespread at diagnosis because the bone marrow itself is the site of the disease.
The five-year relative survival rate for multiple myeloma is 62.4%, based on National Cancer Institute data from 2015 to 2021. That number has improved substantially over the past two decades thanks to newer treatment approaches.
Why It Gets Confused With Autoimmune Disease
In autoimmune diseases like rheumatoid arthritis or lupus, the immune system mistakenly attacks the body’s own tissues. In multiple myeloma, the immune system’s plasma cells have become cancerous. Both situations involve immune cells behaving abnormally, which is where the confusion starts. But the distinction matters: autoimmune diseases are driven by misdirected immune responses, while multiple myeloma is driven by genetic mutations that cause cells to multiply without stopping.
Another source of confusion is that multiple myeloma actually weakens the immune system rather than overactivating it. The flood of useless monoclonal protein crowds out functional antibodies, a condition called hypogammaglobulinemia. At the same time, the cancerous cells in the bone marrow physically displace the normal cells that would become healthy immune cells. The result is that people with myeloma are significantly more vulnerable to infections, the opposite of the overactive immune response seen in autoimmune conditions.
The Link Between Autoimmune Conditions and Myeloma Risk
While myeloma is not itself autoimmune, there is a real and researched relationship between the two. Several autoimmune conditions, including rheumatoid arthritis, systemic scleroderma, Sjögren’s syndrome, and lupus, have been linked in the medical literature to plasma cell disorders like myeloma and its precursor state, MGUS (monoclonal gammopathy of undetermined significance).
The leading theory for this connection is called chronic antigenic stimulation. When the immune system stays activated for long periods, as it does in chronic autoimmune disease, plasma cells keep dividing. The more they divide, the greater the chance that a random genetic mutation will push one of those cells toward becoming malignant. A second possibility is that the already dysfunctional immune system in autoimmune diseases may be worse at detecting and eliminating early cancerous clones, allowing them to survive and grow.
That said, the strength of these associations varies. The link between rheumatoid arthritis and myeloma, for instance, is weak. Two large meta-analyses found no statistically significant increase in myeloma risk among people with rheumatoid arthritis. So while the theoretical connection is plausible, it does not mean that having an autoimmune disease puts you at high risk of developing myeloma.
How Myeloma Develops Over Time
Multiple myeloma almost always begins as MGUS, a condition where abnormal plasma cells produce small amounts of monoclonal protein but haven’t yet caused organ damage. MGUS is surprisingly common, especially in older adults, and most people who have it never develop cancer. On average, about 1% of people with MGUS progress to multiple myeloma each year.
Between MGUS and full myeloma, there is an intermediate stage called smoldering myeloma, where the abnormal protein levels are higher and more malignant plasma cells are present, but the characteristic organ damage hasn’t started. This slow, stepwise progression is one of the things that makes myeloma different from autoimmune diseases, which tend to flare and remit rather than following a linear path from precursor to full disease.
Where the Two Can Overlap in Practice
Some people with myeloma or MGUS develop autoimmune symptoms alongside their plasma cell disorder. The monoclonal protein produced by myeloma cells can sometimes act as an autoantibody, binding to the body’s own tissues and triggering inflammation or nerve damage. This can mimic autoimmune disease and complicate diagnosis, particularly early on when the cancer itself may not be obvious.
There is also overlap in treatment. Corticosteroids, which suppress immune activity, are a cornerstone of therapy for many autoimmune diseases and are also used extensively in myeloma treatment regimens. In autoimmune disease, they calm an overactive immune response. In myeloma, they directly kill malignant plasma cells and reduce inflammation caused by the tumor. The same drug class, used for fundamentally different reasons.
This overlap in symptoms and treatments can reinforce the impression that the two conditions are related in nature. They share immune system territory, but the core problem is different: one is the immune system turned against you, the other is the immune system turned into cancer.